New-onset hematologic disorders following COVID-19 vaccination: a systematic review DOI Creative Commons
Nelson Luis Cahuapaza-Gutierrez, Cielo Cinthya Calderon-Hernandez, Renzo Pajuelo-Vásquez

et al.

Clinical and Experimental Vaccine Research, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 1, 2025

Coronavirus disease 2019 (COVID-19) vaccination reduced morbimortality rates due to severe acute respiratory syndrome coronavirus 2 infection worldwide. However, various complications have been reported, including hematologic disorders. We conducted a systematic review synthesize and analyze the current available evidence on development of hematological disorders associated with COVID-19 vaccination. A total 227 patients were reported in papers that selected be included. There was slight predominance females (n=114, 50.22%) compared males (n=113, 49.78%), calculated mean age 54.86±18.94 years. The most frequently Immune thrombocytopenic purpura (n=58, 25.55%), followed by thrombotic (n=38, 16.74%). less recorded cases acquired factor XIII/13 deficiency (n=2, 0.88%) pernicious anemia 0.88%). Messenger RNA (mRNA)-based vaccines, Pfizer BioNTech 162b2 (n=106, 46.70%), Moderna mRNA 127-3 (n = 42, 18.50%), Bivalent vaccine 1, 0.44%), prevalent (n=150, 66.08%). Most developed after first dose (n=120, 52.86%). In cases, patient outcomes favorable (n=175, 77.09%), but there significant mortality (n=23, 10.13%). Our findings suggest close monitoring who receive technology regardless sex, especially adults, as they appear more vulnerable developing PROSPERO Identifier: CRD42023452589.

Language: Английский

Impacts of COVID-19 on People Living with Disability DOI
Prosper Mandela Amaltinga Awuni, James Mbinta

Published: Jan. 1, 2025

Language: Английский

Citations

0
Cost-effectiveness of preventive COVID-19 interventions: a systematic review and network meta-analysis of comparative economic evaluation studies based on real-world data DOI Creative Commons
Xiaoyu Tang, Sun Sun, Mevludin Memedi

et al.

Journal of Global Health, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 20, 2025

There is a knowledge gap regarding the effectiveness and utility of various preventive interventions during COVID-19 pandemic. In this study, we aimed to evaluate cost-effectiveness interventions, including non-medical (NMIs) vaccination programs, using real-world data across different demographic socioeconomic contexts worldwide. We searched Medline, Cochrane Library, Embase, Web Science Core Collection from December 2019 March 2024. identified 75 studies which compared 34 interventions. conducted network meta-analysis assess incremental net benefits (INB) these both societal health care system perspectives. adjusted purchasing power parity (PPP) standardised willingness pay (WTP) enhance comparability economic levels. performed sensitivity subgroup analyses examine robustness results. Movement restrictions expanding testing emerged as most cost-effective strategies perspective, with WTP-standardised INB values USD 21 050 11 144. contrast, combinations NMIs were less cost-effective, particularly in high-income regions. From plus distancing test, trace, isolate strategy highly while masking requirements economically viable. The varied significantly contexts, underlining necessity for region-specific strategies. highlight significant variations Tailoring specific regional infrastructural conditions crucial. Continuous evaluation adaptation are essential effective management ongoing future public threats. PROSPERO: CRD42023385169.

Language: Английский

Citations

0
Assessing the Macroeconomic Impact of COVID-19 Pandemic on the Nigerian Economy through the Lens of SIR-Macro Model DOI Creative Commons
Chijioke O. Nwosu, Nir Samuel,

Donatus Onogbosele

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 18(1), P. 106 - 130

Published: Feb. 21, 2025

The COVID-19 pandemic caused economic and social disruptions in Nigeria forcing the government to implement certain containment measures reduce severity of epidemic. triggered recession leading into a policy dilemma choosing between reducing fatalities stabilizing economy. Thus, key objectives this research focused on analyzing macroeconomic impact Nigerian economy evaluating effectiveness policies infection rates their attendant trade-off with performance. To achieve objectives, study implemented SIR-macro model interaction agents’ decisions parameters models were calibrated based characteristics Nigeria’s structure analyze implications dynamics epidemics. result showed that population those infected peaked at 5.56% week 34 while activities dipped by 5.18% no-containment model. However, benchmark treatment vaccination, 3.09% 42 declined 22.32%. found effective epidemic terms spread disease number deaths. other hand exacerbated recession. Given findings, it was concluded predictions are qualitatively sufficient explaining outcomes during period. suggests should consider socio-demographic country selection an condition. strengthen health care system adequate infrastructure prevent large case fatalities.

Language: Английский

Citations

0
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial DOI Creative Commons

Gonzalo Pérez Marc,

Lorena M. Coria, Ana Ceballos

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 54, P. 127045 - 127045

Published: April 1, 2025

Language: Английский

Citations

0
Charting the future of censuses: Insights, lessons and recommendations for the 2030 round DOI
Pierre D Dindi, Nancy Stiegler

Statistical Journal of the IAOS, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Population censuses globally remain the primary source of official statistics despite existence sample surveys and administrative data sources, like population registers. The 2020 round was predominantly characterised by traditional approaches in about 69% countries, where obtained directly from respondents regardless push to explore alternative sources compelled COVID-19. From Babylonian times 3800 BC date, principal purpose a census has been foster public administration. While 1666 New France (now Quebec) marked first-ever scientifically sound enumeration, it still fell short what presently typifies census. Besides, lack standardised methods dwarfed acceptability comparability results, leading harmonisation efforts gradual adoption modern mid-1800s. Subsequently, United Nations developed maiden international standards on soon after World War II established decennial Housing Census Programme. Overtime, evolved embodies universality, individual simultaneity, periodicity capacity produce small area statistics. As countries transition towards 2030 round, this paper reviews global developments, lessons, provides recommendations for future implementation.

Language: Английский

Citations

0
Changes in seasonal influenza vaccination uptake among older adults during and after the COVID-19 pandemic: Repeated random telephone surveys DOI Creative Commons
Xue Liang,

Cichong Cai,

Fuk-yuen Yu

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: Jan. 6, 2025

People's risk of contracting seasonal influenza increased after COVID-19 control measures were relaxed. This study investigated the changes in vaccination (SIV) uptake and its determinants among older adults during period. Two rounds random telephone surveys conducted 440 373 community-living individuals aged ≥65 y, first between November 2021 January 2022 second October 2023 2024. The difference SIV rate was not significant when comparing round with (50.1% versus 45.0%, p = .48). Concerns related to cost inconvenience receiving associated lower round, but round. Perceived higher co-infection, perceived more severe consequences influenza, benefits, suggestions from others having self-efficacy SIV, both surveys. that vaccinations would have negative impacts on each other, along concerns about side-effects rebound post-pandemic era highlights needs improve adults.

Language: Английский

Citations

0
Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial DOI Creative Commons

Fengcai Zhu,

Ting Huang, Pengfei Jin

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 43 - 43

Published: Jan. 7, 2025

Background: SCTV01E is a tetravalent recombinant COVID-19 vaccine authorized for emergency use in China adults 18 years and older but not those under 18. Objective: This Phase 2 trial assessed the safety immunogenicity of healthy children adolescents aged 3 to 17 years, establish immunobridging with that observed from efficacy pivotal (NCT05308576). Methods: Participants were randomly assigned receive either 30 µg or placebo. Primary endpoints focused on geometric mean titer (GMT) seroresponse rate (SRR) neutralizing antibodies (nAb) against Omicron BA.5. Results: In total, 268 participants (214 vs. 54 placebo) included analysis, 241 (191 50) analysis. Overall, 127 (59.3%) receiving 9 (16.7%) placebo reported adverse events (AEs), most which Grade 1 2. No serious (SAEs) special interest (AESIs) reported. bridging data 95 youths compared 188 adults; ratio (GMR) titers was 8.78 (95% CI: 6.05-12.74, p < 0.001), lower bound 95% CI exceeding 0.67. The difference SRR 6.34% 0.93-11.22%) (p = 0.029), 95%CI >-5%, indicating superiority. Conclusions: found be safe well tolerated adolescents, generating robust immune response supports its potential younger populations.

Language: Английский

Citations

0
Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate DOI Creative Commons
Marcin Bazylewicz, Monika Zajkowska, Monika Gudowska-Sawczuk

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 153 - 153

Published: Jan. 9, 2025

The impact of vaccines against SARS-CoV-2 on the immunity patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to use immunosuppressive and immunomodulatory medications, known as disease-modifying therapies (DMTs), in PwMS, well ensure adequate protection severe outcomes COVID-19. Therefore, aim our study was evaluate humoral cellular immune response PwMS treated DMTs. concentrations IgG Spike (S) anti-SARS-CoV-2 antibodies Nucleocapsid (N) antibodies, interferon-gamma (IFN-γ) titers were analyzed groups dimethyl fumarate (DMF), interferon beta (IFN), healthy control group. Almost 100% experienced seroconversion, which resulted from either vaccination and/or prior infection. Additionally, there no significant differences between terms antibody levels. However, lower both groups, may indicate decreased examined PwMS. after division whole group into two subgroups according time since last vaccination, IFN-γ significantly case who immunized more than 200 days before sample collection. No observed collection less when compared This a time-related decrease

Language: Английский

Citations

0
Rational design and synthesis of pyrazole derivatives as potential SARS-CoV-2 Mpro inhibitors: An integrated approach merging combinatorial chemistry, molecular docking, and deep learning DOI
Arthur Antunes Ferrarezi, João Vítor Perez de Souza, Bernard Maigret

et al.

Bioorganic & Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 120, P. 118095 - 118095

Published: Feb. 4, 2025

Language: Английский

Citations

0
Effect of COVID-19 vaccination coverage on transmission and mortality during Omicron dominance DOI Creative Commons
Stephen Chukwuma Ogbodo, Joseph Junior Damba, Omotayo Olaoye

et al.

Academia Medicine, Journal Year: 2025, Volume and Issue: 2(1)

Published: Feb. 24, 2025

Background: During the coronavirus disease 2019 (COVID-19) pandemic, emergence of Omicron SARS-CoV2 variant raised concerns about reduction in vaccine effectiveness due to its higher transmissibility. Thus, using ecologic data, we assessed population-level impact COVID-19 vaccination coverage on transmission and mortality, during period dominance globally. Subject methods: We used a longitudinal dataset 110 countries over 16 months (January 2022 April 2023). Applying random-effects regression models, effect monthly full rates newly confirmed cases deaths, adjusting for country characteristics. obtained data from open-access databases, including World Health Organization (WHO) Dashboard Oxford Government Response Tracker. Results: On average, each 1% point increase was associated with 1.4% (95% confidence interval (CI): 0.1%–2.8%, p = 0.035) rate new 5% CI: 3.6%–6.4%, < 0.001) deaths. This protective graded across levels coverage: compared <50% coverage, those coverages 50%–59%, 60%–69%, 70%–79%, ≥80% had 20.5% –16.4%–45.7%), 53.8% (22.6%–72.5%), 54.3% (15.5%–75.3%), 69.6% (38.7%–84.9%) lower cases, respectively, average. Conclusions: Our findings suggest an important role mitigating pandemics, particularly despite highly transmissible variants like Omicron.

Language: Английский

Citations

0